ArticleFrontiers in oncology2025
Risk factors for postoperative recurrence of desmoid tumors: a retrospective cohort analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Desmoid tumors (DTs) are rare soft-tissue neoplasms characterized by local invasiveness and high recurrence potential. Due to heterogeneous clinical behavior and unresolved controversies regarding postoperative recurrence risk factors, optimal management remains challenging. This study aimed to identify predictors of recurrence-free survival (RFS) after grossly complete recection. Methods: We retrospectively analyzed 81 DT patients undergoing resection at our institution (September 2014-December 2024). Clinicopathological variables were assessed using Cox regression for recurrence risk, with RFS compared via Kaplan-Meier analysis. Results: The median follow-up was 55 months (range: 4-127 months). The 1-year, 3-year, and 5-year RFS rates for the entire cohort were 89.8% (95% CI: 83.1-96.5), 73.8% (95% CI: 63.6-84.0), and 65.5% (95% CI: 53.5-77.5), respectively. Univariate Cox regression analysis showed that larger tumor size (per 1 cm increase: HR = 1.271, Conclusion: In this cohort, tumor size and extremity location were identified as independent predictors of worse recurrence-free survival in patients with desmoid tumors following macroscopic complete resection. These robust factors may aid in postoperative risk stratification and inform patient counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.